Request for CMS to provide a Bayh-Dole Section 202 license and a 28 USC 1498 authorization and consent to use three patents listed in the FDA Orange Book for the cancer drug enzalutamide

Letter from KEI, UACT and UAEM to Chiquita White Brooks-Lasure, Administrator of the Office of the Administrator, Centers for Medicare and Medicaid Services, at HHS, asking that CMS to provide a Bayh-Dole Section 202 license and a 28 USC 1498… Continue Reading

KEI Comments to the NIH on Exclusive License to UK Firm Poolbeg Pharma

On April 8, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to Poolbeg Pharma Limited, a UK-based company. The license concerns, “Adoptive T Cell Therapy Products… Continue Reading

WTO General Council (March 2024): Colombia’s intervention on TRIPS for Development: Post MC13 work on TRIPS-related Issues – Communication from Bangladesh, Colombia, Egypt and India

On Friday, 22 March 2024, Ambassador Mauricio Alberto Bustamante Garcia, Permanent Mission of Colombia to the World Trade Organization (WTO) delivered the following statement at the WTO General Council in relation to the submission by Bangladesh, Colombia, Egypt, and India… Continue Reading

INB 9 – Oral statement by Knowledge Ecology International

On Monday, 18 March 2024, Knowledge Ecology International (KEI) delivered the following oral statement (in person) at the 9th meeting of the World Health Organization’s (WHO) Intergovernmental Negotiating Body (INB). With respect to Article 11.2, the current references to “to… Continue Reading